EU TPD Compliance: What Nicotine Manufacturers Need to Know

Selling nicotine products in the EU without TPD compliance isn't a gray area. It's a market access barrier with real enforcement behind it. And your compliance starts upstream, with the nicotine ingredient itself.

The Tobacco Products Directive (Directive 2014/40/EU) governs nicotine-containing products across all 27 EU member states. Article 20 covers electronic cigarettes and refill containers. Tobacco-free nicotine pouches sit outside the directive entirely, and member states have filled that gap with national rules ranging from outright bans to numeric nicotine limits to notification regimes. If you're manufacturing nicotine products for the European market, these are the rules you're playing by, and the rules that are coming.

The Hard Limits

Concentration and Volume Caps

The TPD draws firm lines for e-cigarettes and refill products:

• 20 mg/mL maximum nicotine concentration for consumer e-liquids
• 10 mL maximum for refill containers
• 2 mL maximum for pre-filled cartridges and pods

No exceptions. No variances. Your formulations must hit these targets after accounting for manufacturing tolerances and analytical variability. If your nicotine supplier delivers inconsistent purity between batches, staying under 20 mg/mL becomes a math problem you shouldn't have to solve.

Consider the practical implications. If your target formulation is 18 mg/mL and your nicotine input varies by plus or minus 3% in purity between batches, every production run requires recalculation and adjustment. Over the course of a year with 50+ production batches, that variability translates directly into either over-concentration risk (regulatory violation) or under-concentration (consumer dissatisfaction and off-label delivery). Starting with pharmaceutical-grade nicotine that consistently meets 99.5%+ purity eliminates this variable from your quality equation.

The 6-Month Notification Requirement

Before placing any product on the EU market, you must submit a notification to the competent authority in each member state where you plan to sell. Six months before launch.

Get the nature of this obligation right, because it drives how you plan. Article 20 sets up a notification regime, not an authorization regime. No authority issues an approval, no marketing license is granted, and nothing is "cleared." You file complete data, you wait out the standstill period, and you are then responsible for the product's compliance. Filing is not a defense if the product turns out not to comply. The notification includes:

• Full ingredient list with CAS numbers, quantities, and function
• Toxicological data for ingredients in both heated and unheated form
• Nicotine dose and uptake information, including pharmacokinetic data where available
• Manufacturing process description with sufficient detail for regulatory evaluation
• Quality and safety declaration signed by the responsible person
• Available scientific and market studies on the product, if any exist

Miss the 6-month window and your launch timeline slips by at least that long. For multi-market launches across multiple member states, the coordination required is substantial. Each notification is country-specific and submitted through the EU Common Entry Gate (EU-CEG).

Be precise about what EU-CEG is. The Commission describes it as a technical platform for delivering a message from a submitter to a member state; assessment of the data and application of national law sit with the member state, separately. EU-CEG does not approve anything, does not validate your compliance, and returning a submission ID is not a regulatory sign-off. Suppliers and consultants who talk about "EU-CEG approval" are describing something that does not exist.

The system does have specific formatting requirements. Ingredient data, emission data, and product design parameters must conform to defined templates, and a submission that fails validation is not a submission. In practice a malformed filing means resubmitting, and the six-month period runs from a complete notification, not from your first attempt.

Emissions Testing

You must provide emission measurements for nicotine and other compounds generated during product use. Standardized testing methods apply, with ISO 20768 being the reference standard for e-cigarette emission testing.

Emission profiles depend on multiple factors: the nicotine concentration, the carrier composition (PG/VG ratio), the heating element characteristics, and the device power output. Your nicotine source documentation feeds directly into these submissions because the purity and composition of your nicotine input affects the emission profile. Impurities in the nicotine can generate unexpected thermal degradation products that show up in emission testing and require explanation in the notification.

Emission testing should be conducted by accredited laboratories using validated methods. Cost per product variant varies widely with testing scope, analyte count and laboratory, so get quotes rather than working from a rule of thumb. What is predictable is that the bill scales with the number of variants, and budgeting for an entire portfolio (multiple flavors, multiple nicotine strengths, multiple device configurations) adds up quickly. Getting the test right the first time by starting with well-characterized, high-purity nicotine inputs saves both money and time.

Labeling Requirements

TPD-mandated labeling includes:

• Health warnings covering 30% of the corresponding surface of the unit packet and any outside packaging, rising to 32% in member states with two official languages and 35% in those with more than two
• Specific warning text: "This product contains nicotine which is a highly addictive substance"
• Nicotine concentration in mg/mL, accurately reflecting the actual content
• Complete ingredient listing in descending order of weight
• Batch/lot numbers enabling traceability from finished product back to component ingredients
• Expiry or "best before" date based on documented stability data
• Manufacturer or responsible person name and contact information
• Leaflet with instructions for use, contraindications, adverse effects, and target consumer information

Labeling accuracy is subject to enforcement testing. Regulatory authorities in member states conduct market surveillance that includes purchasing products from retail and testing labeled nicotine content against actual content. The directive does not itself set a numerical tolerance, so the acceptable deviation is a matter of national enforcement practice and varies between member states. Check the position in each market you sell in. Deviations judged material result in enforcement action ranging from product recall to market withdrawal to financial penalties.

How Your Nicotine Source Affects Compliance

Documentation for Notifications

TPD notifications require detailed ingredient data that goes well beyond a simple specification sheet. Your supplier needs to provide:

• Batch-specific COAs covering purity, impurity profile (with individual named impurities and limits), heavy metals, residual solvents, and water content
• Manufacturing description detailing extraction source material, extraction method, purification steps, and in-process quality testing at each stage
• Stability data showing how nicotine characteristics (purity, impurity growth, color, pH) change under specified storage conditions over time. ICH Q1A guidelines for stability testing provide the framework, even though they were written for pharmaceuticals
• Toxicological data for the nicotine product as supplied, including acute toxicity, genotoxicity, and any available chronic exposure data
• Residual solvent analysis per ICH Q3C, with quantified levels of any solvents used in the extraction and purification process

If your supplier can't produce these documents for each batch, your notification is incomplete. An incomplete notification is not a notification: the six-month period does not begin, and placing the product on the market anyway leaves you exposed on market entry rather than merely delayed. Member state authorities are under no obligation to itemize what is missing, which is why the gap is usually found late and by someone else.

Pharmacopoeial Grade Simplifies Everything

The TPD doesn't explicitly require USP or EP grade nicotine. But using pharmacopoeial-grade material gives you a recognized purity benchmark, a well-documented impurity profile, and validated analytical methods out of the box.

EP (European Pharmacopoeia) grade nicotine is particularly relevant for TPD compliance because:

• The EP monograph defines specific tests and limits for identified impurities, giving you a ready-made impurity profile for your notification
• EP methods are recognized by EU regulatory authorities, reducing questions about analytical validity
• EP-grade material is manufactured under GMP conditions, which strengthens the quality and safety declaration in your notification
• The EP assay limits for nicotine, 99.0% to 101.0% calculated on the anhydrous basis, give you a narrow and externally defined band to formulate against rather than a supplier's own word for it

EP-compliant nicotine is the path of least resistance in the European market, because every document you would otherwise have to build from scratch already exists in a form regulators recognize.

Batch Traceability Connects Your Chain

TPD products must carry batch numbers that enable end-to-end traceability. That traceability has to reach back to the nicotine ingredient level. Your supplier's batch documentation must link cleanly to your finished product records.

In practical terms, this means your manufacturing records for each production batch must include the specific nicotine ingredient batch number(s) used, the corresponding COA(s), and the supplier's batch release documentation. If a quality issue is identified in the market, you need to be able to trace backward from a consumer complaint through your finished product batch to the specific nicotine ingredient batch and its full quality documentation.

This traceability requirement also applies to the nicotine salts and nicotine dilutions used in e-liquid manufacturing. Each component entering your process must be traceable to its source and supported by batch-level quality documentation.

Post-Market Obligations

Getting to market is step one. Staying compliant means ongoing work:

• Annual reporting. Sales volume data by member state and brand, submitted each year through the EU-CEG system. The reporting deadline varies by member state but typically falls in the first quarter of the following year.
• Adverse effect monitoring. You must maintain a system for collecting and reporting suspected adverse effects from consumers, healthcare providers, and other sources. Serious adverse effects must be reported promptly. This requires an internal pharmacovigilance-like system with defined procedures, responsible personnel, and documented case handling.
• Notification updates. Any change to product composition, manufacturing process, or supplier that could affect the product's characteristics requires an updated notification. Using a new nicotine supplier or a new batch from an existing supplier that falls outside previously notified specifications triggers this requirement.
• Member state variations. Some countries add requirements beyond the base TPD, and some go considerably further. The Netherlands restricted e-liquid flavors to tobacco. Belgium has additional labeling requirements. France prohibits oral consumer nicotine products outright as of April 2026. Denmark, Hungary, Czechia, Finland and Latvia each set their own numeric limits for nicotine pouches, expressed in units that are not interchangeable. Monitor each market you sell in and track regulatory developments through industry associations or regulatory intelligence services.

Market Surveillance and Enforcement

EU member states conduct active market surveillance of nicotine products. This includes:

• Purchasing products from retail for laboratory analysis
• Verifying labeled nicotine content against actual content
• Checking compliance with packaging and labeling requirements
• Reviewing whether products match their EU-CEG notifications
• Investigating consumer complaints and adverse event reports

Penalties for non-compliance vary by member state but can include product seizure, market withdrawal orders, financial penalties, and in serious cases, criminal prosecution of responsible individuals. The enforcement landscape has become more active since 2020, with several member states investing in expanded testing capacity and dedicated enforcement teams.

Nicotine Pouches and the Evolving EU Regulatory Landscape

Nicotine pouches occupy an evolving regulatory position in the EU. Because they contain no tobacco leaf and are not electronic devices, they fall outside the explicit scope of TPD Article 20. However, several member states have addressed this gap:

• The Netherlands banned the sale of nicotine pouches with effect from January 1, 2025, under a decree adopted in October 2024
• Belgium has prohibited the sale of nicotine pouches since 2023
• France prohibits the production, sale, possession and use of oral nicotine products from April 1, 2026, under Décret n° 2025-898
• Denmark caps pouches at 9.0mg of nicotine per pouch and limits flavors to tobacco and menthol or mint, under Lov nr. 1669 of December 2024, with full compliance required since April 2026
• Austria brought tobacco-free nicotine products under its tobacco act from August 20, 2026, requiring an EU-CEG notification six months before market entry at a fee of EUR 3,000 per product variant
• Latvia, Finland, Czechia and Hungary set numeric nicotine limits of 4mg per gram, 16.6mg per gram, 12mg per dose and 17mg per pouch respectively
• Germany classifies nicotine pouches as food products, applying food safety regulations
• Sweden, where snus has long-standing legal status, treats pouches under its Act on tobacco-free nicotine products and sets no statutory concentration limit

The Commission is working on it, and the stage is worth stating precisely rather than in the vague terms most coverage uses. It published its evaluation of the tobacco directives on April 2, 2026, ran a call for evidence that closed on June 15, 2026, and closed a twelve-week public consultation on August 14, 2026. The indicative timetable for a legislative initiative is December 2026, and the Commission states expressly that all elements, including timing, are subject to change. Extending scope to novel products such as nicotine pouches is one of the named policy areas, but no proposal has been published and no nicotine limit, flavor rule or packaging specification has been put forward. Pan-EU regulation of pouches looks like a matter of when rather than if, but nobody yet knows what it will say, and our breakdown of what the TPD3 workstream actually contains separates the record from the speculation. Building documentation and quality systems to TPD-equivalent standards now, even where not currently required, positions you for whatever arrives.

For pouch manufacturers using nicotine bitartrate dihydrate or nicotine polacrilex, maintaining EP-grade sourcing and full batch documentation creates a regulatory-ready foundation regardless of which specific framework each member state adopts.

Building Your TPD Compliance Strategy

Choose suppliers who understand European regulation. Not all nicotine suppliers know what a TPD notification requires. The ones who do can save you weeks of back-and-forth documentation requests. Ask prospective suppliers to provide a sample documentation package formatted for EU-CEG submission. If they don't know what EU-CEG is, that tells you everything.

Build notification timelines into product planning. That 6-month lead time is non-negotiable. Factor it into every launch schedule. For a product launching in Q1, the notification must be submitted no later than the previous Q3. Add preparation time for documentation assembly, emissions testing, and internal review, and your planning horizon extends to 9 to 12 months before launch.

Track member state differences. The TPD is a directive, not a regulation. Each country transposes it into national law with some flexibility in implementation. What works in Germany may need adjustment for France. Maintain a regulatory matrix that maps requirements by country and update it quarterly.

Centralize your regulatory documentation. Create a single system of record for all TPD-related documents: notifications, COAs, emission reports, stability data, labeling approvals, and post-market surveillance records. When an auditor or authority requests information, you should be able to produce it in hours, not weeks.

Use EP-grade nicotine as your baseline. It covers the broadest range of EU requirements and simplifies your documentation burden.

Understanding how different countries regulate nicotine products globally helps you build a documentation strategy that works across borders. Companies also selling in the US market can align their TPD documentation with PMTA requirements to reduce duplication of effort.

Frequently Asked Questions